{
    "pmcid": "8907017",
    "qa_pairs": {
        "How does the bispecific nanobody enhance its neutralization potency against SARS-CoV-2 variants?": [
            "By simultaneously and synergistically binding to two epitopes on a single RBD",
            "By binding to a single conserved epitope on the spike protein",
            "By targeting the viral RNA replication machinery",
            "By inhibiting the host cell entry receptors"
        ],
        "What advantage does the bispecific nanobody have over a cocktail of its individual components?": [
            "It outperformed the cocktail in neutralization assays",
            "It is easier to produce in large quantities",
            "It has a longer half-life in the bloodstream",
            "It requires a lower dosage for efficacy"
        ],
        "What delivery method is used for the bispecific nanobody to target respiratory infections?": [
            "Inhalation delivery",
            "Intravenous injection",
            "Oral administration",
            "Subcutaneous injection"
        ],
        "What is the primary target of the bispecific single-domain antibody developed in the study?": [
            "Conserved regions on the Omicron variant's receptor-binding domain (RBD)",
            "Variable regions on the SARS-CoV-2 spike protein",
            "Non-conserved regions on the Omicron variant's nucleocapsid protein",
            "Highly mutable regions on the SARS-CoV-2 envelope protein"
        ],
        "What structural technique was used to reveal the binding sites of the bispecific antibody on the RBD?": [
            "Cryo-electron microscopy (cryo-EM)",
            "X-ray crystallography",
            "Nuclear magnetic resonance (NMR) spectroscopy",
            "Atomic force microscopy (AFM)"
        ]
    }
}